Corvus PharmaceuticalsCRVS
CRVS
About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Employees: 28
0
Funds holding %
of 6,815 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,029% more call options, than puts
Call options by funds: $6.07M | Put options by funds: $538K
533% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 3
211% more capital invested
Capital invested by funds: $50.9M [Q2] → $158M (+$108M) [Q3]
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
30% more funds holding
Funds holding: 47 [Q2] → 61 (+14) [Q3]
3.36% more ownership
Funds ownership: 44.72% [Q2] → 48.08% (+3.36%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
116%
upside
Avg. target
$12.50
145%
upside
High target
$14
175%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Sean Lee 57% 1-year accuracy 13 / 23 met price target | 116%upside $11 | Buy Reiterated | 14 Jan 2025 |
Oppenheimer Jeff Jones 25% 1-year accuracy 10 / 40 met price target | 175%upside $14 | Outperform Reiterated | 13 Nov 2024 |
Financial journalist opinion
Based on 7 articles about CRVS published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo
Neutral
GlobeNewsWire
1 week ago
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, which is being held in San Francisco from January 13-16, 2025. The Company's presentation will be on Wednesday, January 15 at 2:15 pm ET / 11:15 am PT.
Positive
Seeking Alpha
3 weeks ago
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Corvus is developing next-generation ITK inhibitors which are going to offer a more tailored approach to targeting specific immunological disorders.
Negative
Benzinga
3 weeks ago
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Corvus Pharmaceuticals, Inc. CRVS released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Negative
Benzinga
3 weeks ago
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday.
Neutral
GlobeNewsWire
3 weeks ago
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million Company to host conference call and webcast today at 8:00 a.m. ET / 5:00 a.m.
Neutral
GlobeNewsWire
4 weeks ago
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024
Neutral
GlobeNewsWire
1 month ago
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal
Positive
Zacks Investment Research
2 months ago
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable
Corvus (CRVS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
GlobeNewsWire
2 months ago
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases
Charts implemented using Lightweight Charts™